Case: A 24 year old woman was investigated following grade II anaphylaxis to intramuscular methylprednisolone.
Background: Allergy to penicillin is commonly reported in the community. However, the majority of patients are not allergic when formally tested. In low risk patients, rapid allergy testing has been performed with skin prick/intradermal or direct oral challenge in an outpatient and Emergency Department setting. However, a direct oral challenge in acute hospital inpatient has not been reported.
Aim:
To access the feasibility and safety of rapid penicillin allergy delabelling with direct oral challenge in admitted acute general medical patients.
Methods: Patients admitted to a general medicine unit were screened for a history of penicillin allergy by unit pharmacists. A detailed history was obtained on patients with a self-reported penicillin allergy to assess suitability for a direct oral challenge: including current clinical status, and pretest probability based on the Australian Society of Allergy and Clinical Immunology (ASCIA) Guidelines. Suitable patients where challenged with a single 250mg Amoxicillin oral dose, followed by a 3 days course of 250mg Amoxicillin TDS.
Results: 1808 patients were admitted to a general medicine unit from February to June 2018. 181 (10%) patients had a documented penicillin allergy. Rash (45%) is most commonly reported followed by unknown/ non-specific reaction (21%) and gastro-intestinal symptoms (10%). Only 28 (16%) of patients met criteria for high pre-test probability of reaction. 35 (19%) patients were recruited to a challenge. 34 patients tolerated the challenge without any reactions. Only 1 patient reported a rash. 13 patients had been de-labelled from June 2017 to February 2018 using the same protocol, resulting in total of 47 patients successfully de-labelled since June 2017. Data collection is ongoing.
Conclusion:
Penicillin allergy de-labelling with a direct oral challenge in an acute hospital inpatient setting is likely safe and feasible. This approach may improve patient outcome with better anti-microbial usage and reduce burden on outpatient immunology waiting lists. Immunotherapy was recommenced with the addition of Omalizumab 150 mcg 30 minutes before JJA VIT every fortnight. She achieved a maintenance dose of 50mcg JJAV 10 weeks later. A BAT was repeated 4 weeks following her first maintenance dose demonstrating no JJA venom basophil reactivity. Omalizumab was continued for 6 months. Three months after discontinuing Omalizumab our patient experienced a mild (Brown grade I) systemic reaction. Repeat BAT demonstrated reduction of CD63 positive, reactive, basophils from 44.4% to 18.9% at a dilution of 0.1mcg/ml JJAV.
Recurrent systemic VIT allergic reactions may occur after Omalizumab has been discontinued or reduced. The potential role of BAT for therapeutic monitoring in this setting is promising and requires further investigation.
